An Open Label, Longterm Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects With Moderate to Severe Chronic Low Back Pain.

Trial Profile

An Open Label, Longterm Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects With Moderate to Severe Chronic Low Back Pain.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2012

At a glance

  • Drugs Buprenorphine (Primary)
  • Indications Back pain
  • Focus Therapeutic Use
  • Sponsors BioDelivery Sciences International
  • Most Recent Events

    • 16 Apr 2012 Status changed from not yet recruiting to withdrawn as reported by ClinicalTrials.gov.
    • 16 Apr 2012 Actual initiation date (July 2012) added as reported by ClinicalTrials.gov.
    • 16 Apr 2012 Planned End Date changed from 1 Apr 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top